BioCentury
ARTICLE | Financial News

Pronutria raises $39M series C

May 29, 2015 2:41 AM UTC

Pronutria Biosciences Inc. (Cambridge, Mass.) raised $39 million in a series C round led by new investor Fidelity Management & Research Co. Existing investor Flagship Ventures and other undisclosed investors also participated, including individuals and family offices.

Pronutria is developing amino acid-based therapeutics to treat muscle, metabolic, neurological and liver disorders. President and CEO Robert Connelly said the company expects to begin a proof-of-concept study of PN107 to treat myopenia (muscle wasting) and hopes to start a pivotal study of at least one candidate by 2H16. PN107 is an orally ingested protein with an amino acid combination and physicochemical profile optimized for myopenia conditions. ...